愛美醫療 FOLD 深 滬
已收盤 12-19 16:00:00 美东时间
14.18
+3.290
+30.21%
華盛通- 最 高14.36
- 今 開14.18
- 成交量 1.88亿股
- 最 低 14.16
- 昨 收 10.89
- 總市值 43.82亿
- 52周最高 14.36
- 市盈率 靜 --
- 換手率 60.92%
- 52周最低 5.51
- 委 比 96.38%
- 總股本 3.09亿
- 歷史最高 25.39
- 量 比 20.93
- 振 幅 1.84%
- 歷史最低 1.765
- 每 手 1
- 風險率 1.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | 太空概念股普涨，LUNR涨近38%；爱美医疗涨超30%，获拜玛林制药48亿美元收购
NovaBay Pharmaceuticals涨79.7%；Lunar Corporation涨37.7%；D-MARKET Electronic Services & Trading涨37.1%
12-20 10:49
美股周涨跌榜 | 特朗普媒体科技集团周涨51.1%，拟并购TAE转型聚变能源公司；Medline周涨43.6%
DJT周涨51.1%，拟并购TAE转型聚变能源公司；Medline周涨43.6%，本周首挂上市，为年内全球最大规模IPO；爱美医疗周涨34.4%，获拜玛林制药48亿美元收购>>
12-20 09:40
Needham Downgrades Amicus Therapeutics to Hold
Needham analyst Gil Blum downgrades Amicus Therapeutics (NASDAQ:FOLD) from Buy to Hold.
12-20 00:17
BioMarin Boosts Rare Disease Portfolio With Amicus Buyout, Stocks Rally
BioMarin acquires Amicus for $4.8B, expanding its rare disease portfolio with Fabry and Pompe therapies, in a deal expected to close Q2 2026.
12-20 00:07
Amicus Therapeutics to Be Acquired by BioMarin
Amicus ( ($FOLD) ) has shared an update. On December 19, 2025, Amicus Therapeut...
12-19 22:46
美股异动 | 美光科技续涨超6%！半导体板块领涨大市，英伟达、博通、AMD均涨超2%
美光科技续涨超6%！半导体板块领涨大市，英伟达、博通、AMD均涨超2%；甲骨文大涨超6%，公司参与TikTok美国业务合资交易>>
12-19 22:43
BioMarin to acquire rare disease drug developer Amicus for $4.8B
BioMarin Pharmaceutical (BMRN) has agreed to acquire rare disease drug developer Amicus Therapeutics (FOLD) in an all-cash transaction worth nearly $4.8B, the companies announced on Friday. As part of...
12-19 20:59
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
12-18 10:54
Citigroup Initiates Coverage On Amicus Therapeutics with Buy Rating, Announces Price Target of $17
Citigroup analyst Samantha Semenkow initiates coverage on Amicus Therapeutics (NASDAQ:FOLD) with a Buy rating and announces Price Target of $17.
12-17 23:22
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
